Search Result

Results for "

Ca2 antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcium Channel (77) Calmodulin (9) CaMK (2) CaSR (3) CRAC Channel (1) Na+/Ca2+ Exchanger (5) 5-HT Receptor (6) Acyltransferase (1) Adrenergic Receptor (5) Akt (2) Androgen Receptor (2) Apoptosis (16) Autophagy (20) Bcl-2 Family (2) Beta-lactamase (2) Bombesin Receptor (3) Caspase (7) CCR (10) Chemerin Receptor (1) Complement System (1) CXCR (3) Cytochrome P450 (1) Dopamine Receptor (12) Endogenous Metabolite (4) Enterovirus (4) ERK (3) Estrogen Receptor/ERR (2) Ferroptosis (1) Free Fatty Acid Receptor (2) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (5) Glutathione Reductase (GR) (2) GnRH Receptor (2) GPR35 (1) GPR55 (2) Histamine Receptor (9) HIV (5) iGluR (5) Influenza Virus (1) Interleukin Related (2) Isotope-Labeled Compounds (14) JNK (1) Keap1-Nrf2 (1) Leukotriene Receptor (2) Ligands for Target Protein for PROTAC (1) LPL Receptor (1) mAChR (7) mGluR (1) Mineralocorticoid Receptor (2) mTOR (3) Myosin (3) nAChR (1) Neurokinin Receptor (2) Neurotensin Receptor (2) NF-κB (2) Opioid Receptor (1) Orexin Receptor (OX Receptor) (5) Oxytocin Receptor (2) P2X Receptor (3) P2Y Receptor (6) p38 MAPK (4) PERK (1) PGE synthase (1) Phosphodiesterase (PDE) (4) Phospholipase (1) PI3K (1) Piezo Channel (1) PKA (6) PKC (9) Platelet-activating Factor Receptor (PAFR) (2) Potassium Channel (7) Prostaglandin Receptor (4) Protease Activated Receptor (PAR) (4) Protein Arginine Deiminase (1) Reactive Oxygen Species (ROS) (2) Reference Standards (26) ROCK (6) Sigma Receptor (2) Sodium Channel (11) TNF Receptor (1) Transmembrane Glycoprotein (1) TRP Channel (7) UGT (1) Vasopressin Receptor (1) Wnt (2)
By Research Areas:	Cancer (41) Cardiovascular Disease (43) Endocrinology (21) Infection (9) Inflammation/Immunology (40) Metabolic Disease (21) Neurological Disease (71)
Oligonucleotides:	Nucleotide Analogs (3) Adenine Nucleotide (3)

175

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Calcium Channel CRAC Channel Na+/Ca2+ Exchanger CaSR Calmodulin CaMK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15084B

Dizocilpine Maximum Cited Publications 44 Publications Verification MK-801	iGluR	Neurological Disease
Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive NMDA receptor antagonist, with a K_d of 37.2 nM in rat brain membranes. Dizocilpine acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca ²⁺ flux .

HY-14656

Diltiazem hydrochloride 5+ Cited Publications CRD-401	Calcium Channel	Cardiovascular Disease Cancer
Diltiazem hydrochloride is a *Ca ²⁺* influx inhibitor (slow channel blocker or calcium antagonist).

HY-103319

Calmidazolium chloride 4 Publications Verification R 24571	Autophagy Calmodulin	Neurological Disease Cancer
Calmidazolium chloride (R 24571) is a calmodulin antagonist, antagonizing CaM-dependent phosphodiesterase and calmodulin-induced activation of erythrocyte Ca2+-transporting ATPase with IC₅₀s of 0.15 and 0.35 μM, respectively . Also in anti-cancer research . Calmidazolium binds to calmodulin with a K_d of 3 nM.

HY-10007

NPS-2143 25+ Cited Publications SB-262470A	CaSR	Metabolic Disease
NPS-2143 (SB-262470A), an orally active calcilytic agent, is a selective and potent calcium ion-sensing receptor (CaSR) antagonist. NPS-2143 (SB-262470A) blocks increases in cytoplasmic Ca ²⁺ concentrations (IC₅₀=43 nM) elicited by activating the Ca ²⁺ receptor in HEK 293 cells expressing the human Ca ²⁺ receptor .

HY-120691A

GSK205 10+ Cited Publications	TRP Channel	Metabolic Disease Inflammation/Immunology
GSK205 is a potent, selective TRPV4 antagonist with an IC₅₀ of 4.19 μM for inhibiting TRPV4-mediated Ca ²⁺ influx .

HY-N0607

Ginsenoside Ro 1 Publications Verification Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V	Calcium Channel Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a *Ca ²⁺*-antagonistic antiplatelet effect with an IC₅₀ of 155 μM. Ginsenoside Ro reduces the production of TXA₂ more than it reduces the activities of COX-1 and TXAS.

HY-B0358

Flunarizine 5+ Cited Publications	Calcium Channel Sodium Channel Dopamine Receptor	Cardiovascular Disease Neurological Disease
Flunarizine is a potent dual *Na ⁺/Ca ²⁺* channel (T-type) blocker. Flunarizine is a D₂ dopamine** receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-123071

Box5 Maximum Cited Publications 11 Publications Verification	Wnt	Cancer
Box5 is a potent Wnt5a antagonist. Box5 inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca ²⁺ release. Box5 inhibits cell migration. Box5 has the potential for the research of melanoma .

HY-B0358A

Flunarizine dihydrochloride 5+ Cited Publications	Calcium Channel Sodium Channel Dopamine Receptor	Cardiovascular Disease Neurological Disease
Flunarizine dihydrochloride is a potent dual *Na ⁺/Ca ²⁺* channel (T-type) blocker. Flunarizine dihydrochloride is a D₂ dopamine** receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-119401

CAY10444 4 Publications Verification BML-241	LPL Receptor	Cancer
CAY10444 (BML-241) is a sphingosine-1-phosphate 3 (S1P3) antagonist. CAY10444 inhibits by 37% S1P-induced increases in Ca²⁺ in HeLa cells expressing S1P3 receptors .

HY-10171

NPS-2143 hydrochloride 25+ Cited Publications SB-262470A hydrochloride	CaSR	Metabolic Disease
NPS-2143 hydrochloride (SB-262470A hydrochloride), an orally active calcilytic agent, is a selective and potent calcium ion-sensing receptor (CaSR) antagonist. NPS-2143 hydrochloride (SB-262470A hydrochloride) blocks increases in cytoplasmic Ca ²⁺ concentrations (IC₅₀=43 nM) elicited by activating the Ca ²⁺ receptor in HEK 293 cells expressing the human Ca ²⁺ receptor .

HY-120261

GB-88 2 Publications Verification	Protease Activated Receptor (PAR)	Inflammation/Immunology
GB-88 is an oral, selective non-peptide antagonist of PAR2, inhibits PAR2 activated Ca ²⁺ release with an IC₅₀ of 2 μM .

HY-B1693

Levomepromazine 1 Publications Verification Methotrimeprazine	5-HT Receptor Dopamine Receptor Histamine Receptor Autophagy Enterovirus Calcium Channel	Infection Neurological Disease Inflammation/Immunology
Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and *Ca ²⁺* release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic *Ca ²⁺* levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting .

HY-16935

Mavatrep JNJ-39439335	TRP Channel	Neurological Disease
Mavatrep (JNJ-39439335) is an orally active, selective and potent TRPV1 antagonist with high affinity for hTRPV1 channels (K_i=6.5 nM). Mavatrep antagonizes capsaicin-induced Ca ²⁺ influx with an IC₅₀ value of 4.6 nM. Mavatrep can be used in some studies of neuropathic pain .

HY-121186

Bevantolol hydrochloride	Adrenergic Receptor Calcium Channel	Cardiovascular Disease Neurological Disease Metabolic Disease
Bevantolol hydrochloride is a selective β1 and α1-adrenergic receptor antagonist with pK_i values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent *Ca ²⁺* antagonist .

HY-16639

ML314	GPR35 Neurotensin Receptor	Neurological Disease Endocrinology
ML314 is a potent, BBB-penetrant and β-arrestin biased molecule agonist of NTR1 (EC₅₀ = 1.9 μM). ML314 shows good selectivity against NTR2 and GPR35, but does not stimulate Ca2+ mobilization. ML314 can attenuate amphetamine-like hyperlocomotion in dopamine transporter knockout mice. ML314 attenuates methamphetamine-associated hyperlocomotion and potentiates the psychostimulant inhibitory effects of a ghrelin antagonist in wild type mouse model. ML314 also acts as an allosteric enhancer of endogenous neurotensin. ML314 antagonizes G protein signaling. ML314 can be studied in research for methamphetamine abuse conditions .

HY-120588

BI 639667 1 Publications Verification CCR1 antagonist 8	CCR	Inflammation/Immunology Endocrinology
BI 639667 (compound 19n), a chemical probe, is a CCR1 antagonist, with an IC₅₀ of 1.8 nM in Ca ²⁺ flux assay .

HY-16952A

Bepridil hydrochloride hydrate 5+ Cited Publications (±)-Bepridil hydrochloride hydrate; Org 5730 hydrochloride hydrate	Calcium Channel	Cardiovascular Disease
Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting Ca ⁺ channel antagonist and Na ⁺, K ⁺ channel inhibitor, with antianginal and type I antiarrhythmic effects. Bepridil hydrochloride hydrate also acts as a cardiac *Na ⁺/Ca2* ⁺ exchange (NCX1)** inhibitor. Bepridil hydrochloride hydrate can be used for the research of cardiovascular disorders .

HY-U00212

Aranidipine MPC1304	Calcium Channel	Cardiovascular Disease
Aranidipine (MPC1304) is a Ca ²⁺ channel antagonist with potent and long-lasting antihypertensive effects.

HY-137175

*TMBIM6 antagonist-1*	mTOR	Cancer
TMBIM6 antagonist-1, a potential TMBIM6 antagonist, prevents TMBIM6 binding to mTORC2, decreases mTORC2 activity, and also regulates TMBIM6-leaky Ca ²⁺ .

HY-136909

SR33805	Calcium Channel	Cardiovascular Disease
SR33805 is a potent Ca ²⁺ channel antagonist, with EC₅₀s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca ²⁺ channels. SR33805 can be used for the research of acute or chronic failing hearts .

HY-157453

*CCR4 antagonist* 4** 1 Publications Verification	CCR	Inflammation/Immunology
CCR4 antagonist 4 (compound 22) is a selective and potent antagonist of the CC chemokine receptor-4 (CCR4), with an IC₅₀ of 0.02 μM. CCR4 antagonist 4 also blocks MDC-mediated chemotaxis (IC₅₀: 0.007 μM) and Ca ²⁺ mobilization (IC₅₀: 0.003 μM). CCR4 antagonist 4 can be used for allergic inflammation research .

HY-103316A

Ned 19 3 Publications Verification	Calcium Channel	Cardiovascular Disease Cancer
Ned 19 is a selective membrane-permeant non competitive NAADP antagonist and inhibits NAADP-mediated *Ca ²⁺* signaling, with an IC₅₀ of 65 nM . Ned 19 strongly inhibits tumor growth and vascularization as well as lung metastases in mice .

HY-123071A

Box5 TFA Maximum Cited Publications 11 Publications Verification	Wnt	Cancer
Box5 TFA is a potent Wnt5a antagonist. Box5 TFA inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca ²⁺ release. Box5 TFA inhibits cell migration. Box5 TFA has the potential for the research of melanoma .

HY-B1193R

Terfenadine (Standard) (±)-Terfenadine (Standard); MDL-991 (Standard)	Reference Standards Potassium Channel Histamine Receptor Na+/Ca2+ Exchanger Caspase Apoptosis	Inflammation/Immunology Endocrinology Cancer
Terfenadine (Standard) is the analytical standard of Terfenadine. This product is intended for research and analytical applications. Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC50 of 204 nM . Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca2+ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9 .

HY-14656S

Diltiazem-d3 hydrochloride	Calcium Channel	Cardiovascular Disease
Diltiazem-d₃ (hydrochloride) is the deuterium labeled Diltiazem hydrochloride. Diltiazem hydrochloride is a Ca2+ influx inhibitor (slow channel blocker or calcium antagonist)[1][2].

HY-149483

CVN417	nAChR	Neurological Disease
CVN417 is an orally active α6 subunit-containing nAChR antagonist, modulating phasic dopaminergic neurotransmission in an impulse-dependent manner. CVN417 inhibits Ca(2+) effluents mediated by nAChR subunits with IC₅₀s of 0.086 μM (α6), 2.56 μM (α3) and 0.657 μM (α4), respectively. CVN417 attenuates resting tremor in Rodent models, displays the potential to improve movement dysfunction, in conditions such as Parkinson's disease .

HY-100928

YS 035 hydrochloride	Calcium Channel	Neurological Disease
YS 035 hydrochloride is a *Ca ²⁺* antagonist on cellular uptake and mitochondrial efflux of calcium ions. YS 035 hydrochloride inhibits Ca ²⁺ uptake by muscle cells and inhibits Na ⁺/Ca ²⁺ exchange (K_i=28 µM). YS 035 hydrochloride is a useful tool for research on the mitochondrial Ca ²⁺ transport .

HY-P1076A

CALP2 TFA	Calmodulin	Inflammation/Immunology
CALP2 TFA is a calmodulin (CaM) antagonist (K_d of 7.9 µM) with high affinity for binding to the CaM EF-hand/Ca ²⁺-binding site. CALP2 TFA inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca ²⁺ concentrations. CALP2 TFA potently inhibits of adhesion and degranulation. CALP2 TFA is also a strong activator of alveolar macrophages .

HY-100783B

Bicuculline methobromide (+)-Bicuculline methobromide	GABA Receptor	Neurological Disease
Bicuculline methobromide is a selective GABAA Receptor antagonist with an IC₅₀ value of 3 μM. Bicuculline methobromide induces clonic tonic convulsions in mammals and can also be used to block Ca ²⁺ activated potassium channels. Bicuculline methobromide can be used in studies of epilepsy and other related psychiatric disorders .

HY-12962

NMDA-IN-1	iGluR	Neurological Disease
NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor.

HY-N0215S14

L-Phenylalanine-15N,d8 (S)-2-Amino-3-phenylpropionic acid-¹⁵N,d₈	Isotope-Labeled Compounds Calcium Channel iGluR Endogenous Metabolite	Metabolic Disease
L-Phenylalanine- ¹⁵N,d₈ is the deuterium and ¹⁵N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca2+ channels antagonist with a K_i of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals .

HY-U00354

CP-060	Calcium Channel	Cardiovascular Disease
CP-060 is a potent *Ca ²⁺* antagonist, inhibits Ca ²⁺ overload and possesses antioxidant and cardioprotective activities.

HY-P1479

Calmodulin-Dependent Protein Kinase II (290-309)	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-10388A

TTA-Q6(isomer)	Calcium Channel	Others
TTA-Q6(isomer) is an isomer of TTA-Q6. TTA-Q6 is a selective *T-type Ca ²⁺* channel** antagonist.

HY-Z8176

(Z)-Flunarizine	Sodium Channel	Neurological Disease
(Z)-Flunarizine is the (Z)-isomer of Flunarizine (HY-B0358). Flunarizine is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine is a D2 dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-N0219R

Bicuculline (Standard) (+)-Bicuculline (Standard)	Reference Standards GABA Receptor	Neurological Disease
Bicuculline (Standard) is the analytical standard of Bicuculline. This product is intended for research and analytical applications. Bicuculline ((+)-Bicuculline) is A competing neurotransmitter GABAA receptor antagonist (IC₅₀=2 μM). Bicuculline also blocks Ca2+ activating potassium (SK) channels and subsequently blocks slow post-hyperpolarization (slow AHP). Bicuculline has anticonvulsant activity. Bicuculline can be used to induce seizures in mice .

HY-N3945R

Glaucine (Standard) O,O-Dimethylisoboldine (Standard); S-(+)-Glaucine (Standard); NSC 34396 (Standard)	Reference Standards Phosphodiesterase (PDE) Calcium Channel Adrenergic Receptor Dopamine Receptor Influenza Virus	Infection Inflammation/Immunology
Glaucine (Standard) is the analytical standard of Glaucine. This product is intended for research and analytical applications. Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum with antitussive, bronchodilation and anti-inflammatory properties. Glaucine is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor with Kis of 3.4 μM in human bronchus and polymorphonuclear leukocytes. Glaucine is also a non-selective α-adrenoceptor antagonist, a Ca2+ entry blocker, and a weak dopamine D1 and D2 receptor antagonist. Glaucine has antioxidative and antiviral activities .

HY-120985

Araguspongin B	Calcium Channel	Neurological Disease
Xestospongins and araguspongins are marine natural products first isolated from Pacific basin sponges, and noted to have vasodilatory properties.1 Inositol phosphates (IP) are important signal transduction messengers acting via IP3 receptors to promote the mobilization of Ca2+ from intracellular stores.2 Araguspongin B antagonizes the calcium-releasing action of inositol 1,4,5-trisphosphate at the receptor level in cerebral microsomes, with an IC₅₀ of 0.6 μM. It is nearly as potent as xestospongin C as an antagonist of the IP3 receptor.

HY-101685

Iganidipine	Calcium Channel	Cardiovascular Disease
Iganidipine is a *Ca ²⁺* antagonist.

HY-115745

*Calmodulin antagonist-1*	Calmodulin	Cardiovascular Disease
Calmodulin antagonist-1 (A-5) is a calmodulin (CaM) antagonist. Calmodulin antagonist-1 inhibits calmodulin-activated Ca ²⁺-phosphodiesterase (PDE) (IC₅₀=66 μM). Calmodulin antagonist-1 also inhibits trypsin-treated Ca ²⁺-PDE (IC₅₀=560 μM) in a competitive fashion with respect to cyclic GMP .

HY-P1479A

Calmodulin-Dependent Protein Kinase II(290-309) acetate	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-117099

TMB-8	Calcium Channel	Neurological Disease
TMB-8 is a novel Ca 2+ antagonist. TMB-8 may exert inhibitory effects in smooth muscle by blocking Ca 2+ release from intracellular bound stores.

HY-U00026

Semotiadil recemate fumarate	Calcium Channel	Cardiovascular Disease
Semotiadil recemate fumarate is the recemate of Semotiadil fumarate. Semotiadil fumarate is a novel vasoselective Ca ²⁺ channel antagonist.

HY-14656S1

Diltiazem-(acetoxy-d3) hydrochloride	Isotope-Labeled Compounds Calcium Channel	Cardiovascular Disease
Diltiazem-(acetoxy-d₃) (hydrochloride) is the deuterium labeled Diltiazem hydrochloride. Diltiazem hydrochloride is a Ca2+ influx inhibitor (slow channel blocker or calcium antagonist)[1][2].

HY-19025

CV-159	Calmodulin	Inflammation/Immunology
CV-159 is a unique dihydropyridine *Ca ²⁺* antagonist with an anti-calmodulin (CaM) action, and has antiinflammatory activities.

HY-121720

L 657925	Prostaglandin Receptor	Cardiovascular Disease
L 657925 is a potent thromboxane A2 (TXA2) antagonist. L 657925 selectively abolishes ONO 11113-evoked transient increment in [Ca2 ²⁺] .

HY-19062

SM-6586	Calcium Channel Na+/Ca2+ Exchanger	Cardiovascular Disease
SM-6586 is a calcium channel antagonist and inhibitor of Na ⁺/H ⁺ and *Na ⁺/Ca ²⁺* exchange transport**, potentially for the treatment of cerebrovasular diseases and hypertension.

HY-125836

*CCR4 antagonist* 2**	CCR	Endocrinology Cancer
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits T_reg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC₅₀ values of Ca ²⁺flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively .

HY-115493

TIQ-15	CXCR	Others
TIQ-15 is a potent CXCR4 antagonist with an IC₅₀ value of 6 nM for CXCR4 Ca ²⁺ flux. TIQ-15 inhibits CYP450 2D6 with an IC₅₀ value of 0.32 μM .

Cat. No.	Product Name

HY-L117

Calcium Channel Blocker Library

217 compounds

Calcium channel blockers (CCBs), also called calcium antagonists are compounds that slow the movement of calcium (Ca2+) through calcium channels into the cells of the heart and blood vessel walls. Calcium causes the heart and arteries to squeeze more strongly. By blocking calcium, calcium channel blockers allow blood vessels to relax and open. So calcium channel blockers are usually used to lower blood pressure, relieve chest pain (angina) and control an irregular heartbeat.

MCE supplies a unique collection of 217 calcium channel blockers and antagonists, all of which have the identified inhibitory effect on calcium channel. MCE Calcium Channel Blocker Library is a useful tool for discovery of antihypertensive drugs and cardiovascular disease research.

Cat. No.	Product Name	Type

HY-W250153

Adenosine 3'-phosphate 5'-phosphosulfate lithium

Biochemical Assay Reagents

Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-W250153A

Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate

Biochemical Assay Reagents

Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

Cat. No.	Product Name	Target	Research Area

HY-123071

Box5 Maximum Cited Publications 11 Publications Verification	Wnt	Cancer
Box5 is a potent Wnt5a antagonist. Box5 inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca ²⁺ release. Box5 inhibits cell migration. Box5 has the potential for the research of melanoma .

HY-123071A

Box5 TFA Maximum Cited Publications 11 Publications Verification	Wnt	Cancer
Box5 TFA is a potent Wnt5a antagonist. Box5 TFA inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca ²⁺ release. Box5 TFA inhibits cell migration. Box5 TFA has the potential for the research of melanoma .

HY-P1341

OXA(17-33) Orexin A (17-33) (human, mouse, rat, bovine)	Orexin Receptor (OX Receptor) Sigma Receptor Phospholipase	Neurological Disease
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC₅₀=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca ²⁺ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer

HY-P1076A

CALP2 TFA	Calmodulin	Inflammation/Immunology
CALP2 TFA is a calmodulin (CaM) antagonist (K_d of 7.9 µM) with high affinity for binding to the CaM EF-hand/Ca ²⁺-binding site. CALP2 TFA inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca ²⁺ concentrations. CALP2 TFA potently inhibits of adhesion and degranulation. CALP2 TFA is also a strong activator of alveolar macrophages .

HY-103277A

BIM 23042 TFA 1 Publications Verification	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-103277

BIM 23042	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin?B?(HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-P1479

Calmodulin-Dependent Protein Kinase II (290-309)	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-P1479A

Calmodulin-Dependent Protein Kinase II(290-309) acetate	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-P11405

[D-Arg1,D-Trp5,7,9,Leu11]-Substance P	Neurotensin Receptor	Neurological Disease Cancer
[D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is a potent inhibitor of cell growth in small cell lung cancer (SCLC). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P is also a neuropeptide antagonist, capable of blocking colony formation stimulated by various neuropeptides (including vasopressin and bradykinin). [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the mobilization of Ca ²⁺ and the activation of mitogen-activated protein kinases induced by vasopressin or bradykinin. [D-Arg1, D-Trp5, 7, 9, Leu11]-Substance P inhibits the growth of H-69 xenograft tumors in nude mice .

HY-P1076

CALP2	Calmodulin	Inflammation/Immunology
CALP2 is a calmodulin (CaM) antagonist ( (K_d of 7.9 µM)) with high affinity for binding to the CaM EF-hand/Ca ²⁺-binding site. CALP2 inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca ²⁺ concentrations. CALP2 potently inhibits of adhesion and degranulation. CALP2 is also a strong activator of alveolar macrophages .

HY-P11019

IS4	CXCR Calcium Channel	Cancer
IS4 is a selective CXCR4 competitive antagonist, with an IC₅₀ of 0.65 nM in THP-1 cells and 38.75 nM in Jurkat cells. IS4 is stable in serum and non-cytotoxic. IS4 competitively binds to CXCR4 with CXCL12, thereby inhibiting CXCL12-induced intracellular Ca ²⁺ release and cancer cell migration. IS4 can be used in the research on the prevention of metastasis of breast cancer, prostate cancer, leukemia, and other diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0219

Bicuculline Maximum Cited Publications 37 Publications Verification (+)-Bicuculline	Alkaloids Lamprocapnos spectabilis (L.) Fukuhara Plants Isoquinoline Alkaloids Papaveraceae Source Classification	GABA Receptor
Bicuculline ((+)-Bicuculline) is A competing neurotransmitter GABA_A receptor antagonist (IC₅₀=2 μM). Bicuculline also blocks Ca ²⁺ activating potassium (SK) channels and subsequently blocks slow post-hyperpolarization (slow AHP). Bicuculline has anticonvulsant activity. Bicuculline can be used to induce seizures in mice .

HY-N0607

Ginsenoside Ro 1 Publications Verification Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Endocrinology Source Classification	Calcium Channel Prostaglandin Receptor
Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a *Ca ²⁺*-antagonistic antiplatelet effect with an IC₅₀ of 155 μM. Ginsenoside Ro reduces the production of TXA₂ more than it reduces the activities of COX-1 and TXAS.

HY-N2359

Chelerythrine	Alkaloids Classification of Application Fields Metabolic Disease Macleaya cordata (Willd.) R. Br. Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Papaveraceae Source Classification	Beta-lactamase PKC Bcl-2 Family Apoptosis Autophagy
Chelerythrine is a natural alkaloid, acts as a potent and selective Ca ²⁺/phospholopid-dependent PKC antagonist, with an IC₅₀ of 0.7 μM . Chelerythrine has antitumor, antidiabetic and anti-inflammatory activity . Chelerythrine inhibits the BclXL-Bak BH3 peptide binding with IC₅₀ of 1.5 μM and displaces Bax from BclXL. Chelerythrine triggers apoptosis and autophagy .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular *Ca ²⁺* accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-125703

Ferutinin	Viguiera dentata (Cav.) Spreng. Infection Classification of Application Fields Terpenoids Sesquiterpenes Umbelliferae Plants Disease Research Fields Endocrinology Source Classification Cancer	Estrogen Receptor/ERR Apoptosis
Ferutinin, a natural terpenoid compound, is an estrogen receptor ERα agonist and estrogen ERβ-receptor agonist/antagonist with IC₅₀s of 33.1 nM and 180.5 nM, respectively. Ferutinin acts as an electrogenic Ca ²⁺-ionophore that increases calcium permeability of lipid bilayer membranes, mitochondria. Ferutinin possesses estrogenic, antitumor, antibacterial and antiinflammatory activities .

HY-N4267

Yangambin	Cardiovascular Disease Structural Classification other families Classification of Application Fields Lignans Phenylpropanoids Plants Disease Research Fields Source Classification	Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human UGT1A1, and an IC₅₀ of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB₄-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated *Ca ²⁺* channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .

HY-N0219R

Bicuculline (Standard) (+)-Bicuculline (Standard)	Alkaloids Structural Classification Lamprocapnos spectabilis (L.) Fukuhara Plants Isoquinoline Alkaloids Papaveraceae Source Classification	Reference Standards GABA Receptor
Bicuculline (Standard) is the analytical standard of Bicuculline. This product is intended for research and analytical applications. Bicuculline ((+)-Bicuculline) is A competing neurotransmitter GABAA receptor antagonist (IC₅₀=2 μM). Bicuculline also blocks Ca2+ activating potassium (SK) channels and subsequently blocks slow post-hyperpolarization (slow AHP). Bicuculline has anticonvulsant activity. Bicuculline can be used to induce seizures in mice .

HY-N3945R

Glaucine (Standard) O,O-Dimethylisoboldine (Standard); S-(+)-Glaucine (Standard); NSC 34396 (Standard)	Alkaloids Structural Classification other families Plants Isoquinoline Alkaloids Glaucium flavum Papaveraceae Source Classification	Reference Standards Phosphodiesterase (PDE) Calcium Channel Adrenergic Receptor Dopamine Receptor Influenza Virus
Glaucine (Standard) is the analytical standard of Glaucine. This product is intended for research and analytical applications. Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum with antitussive, bronchodilation and anti-inflammatory properties. Glaucine is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor with Kis of 3.4 μM in human bronchus and polymorphonuclear leukocytes. Glaucine is also a non-selective α-adrenoceptor antagonist, a Ca2+ entry blocker, and a weak dopamine D1 and D2 receptor antagonist. Glaucine has antioxidative and antiviral activities .

HY-N0607R

Ginsenoside Ro (Standard) Polysciasaponin P3 (Standard); Chikusetsusaponin 5 (Standard); Chikusetsusaponin V (Standard)	Panax ginseng C. A. Meyer Triterpenes Structural Classification Terpenoids Plants Araliaceae Source Classification	Reference Standards Calcium Channel Prostaglandin Receptor
Ginsenoside Ro (Standard) is the analytical standard of Ginsenoside Ro. This product is intended for research and analytical applications. Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.

HY-N10754

Aschantin	Structural Classification Magnoliaceae Lignans Yulania biondii (Pamp.) D. L. Fu Phenylpropanoids Plants Source Classification	mTOR Cytochrome P450
Aschantin, a bisepoxylignan, can be isolated from Magnolia biondii. Aschantin has antiplasmodial, Ca ²⁺-antagonistic, platelet activating factor-antagonistic, and chemopreventive activities. Aschantin is a mTOR kinase inhibitor. Aschantin is also an inhibitor of Cytochrome P450 and UGT enzyme .

HY-N18279

Bulbocapnine	Structural Classification Alkaloids Corydalis yanhusuo W. T. Wang Quinoline Alkaloids Plants Papaveraceae Source Classification	Dopamine Receptor Adrenergic Receptor
Bulbocapnine is an aporphine isoquinoline alkaloid that exerts antagonistic effects on dopamine Receptor) and α-adrenergic receptors, as well as anti-peroxidative effects. The K_i value of bulbocapnine for tyrosine hydroxylase (TH) is 0.20 mM. Bulbocapnine reduces intracellular dopamine content, inhibits TH activity, and decreases *Ca ²⁺* concentration. Bulbocapnine antagonizes the dose-dependent inhibitory effect of dopamine on the heart rate acceleration induced by stimulating the postganglionic fibers of the right cardiac accelerator nerve .

HY-N9554

WIN-64821	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source Classification	Neurokinin Receptor Endogenous Metabolite Calcium Channel
WIN-64821 is a secondary metabolite produced by Aspergillus species, and acts as a Neurokinin Receptor antagonist. The K_i values of WIN-64821 for NK1, NK2 and NK3 receptors are 0.24 (human astrocytoma cells), 0.26 (rat duodenum) and 15.2 (guinea pig forebrain) μM, respectively. WIN-64821 inhibits apamin-induced contraction of rat vas deferens, blocks substance P-induced contraction of guinea pig ileum and Ca ²⁺ efflux in human astrocytoma cells. WIN-64821 is applicable to analgesic and anti-inflammatory research .

Cat. No.	Product Name	Chemical Structure

HY-14656S

Diltiazem-d3 hydrochloride
Diltiazem-d₃ (hydrochloride) is the deuterium labeled Diltiazem hydrochloride. Diltiazem hydrochloride is a Ca2+ influx inhibitor (slow channel blocker or calcium antagonist)[1][2].

HY-N0215S14

L-Phenylalanine-15N,d8

L-Phenylalanine- ¹⁵N,d₈ is the deuterium and ¹⁵N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca2+ channels antagonist with a K_i of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals .

HY-14656S1

Diltiazem-(acetoxy-d3) hydrochloride
Diltiazem-(acetoxy-d₃) (hydrochloride) is the deuterium labeled Diltiazem hydrochloride. Diltiazem hydrochloride is a Ca2+ influx inhibitor (slow channel blocker or calcium antagonist)[1][2].

HY-B0358AS

Flunarizine-d8 dihydrochloride
Flunarizine-d₈ dihydrochloride is deuterated labeled Flunarizine dihydrochloride (HY-B0358A). Flunarizine dihydrochloride is a potent dual *Na ⁺/Ca ²⁺* channel (T-type) blocker. Flunarizine dihydrochloride is a D₂ dopamine** receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-178251S

L-Phenylalanine-d

L-Phenylalanine-d is the deuterium labeled L-Phenylalanine (HY-N0215). L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca ²⁺ channels antagonist with a K_i of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals .

HY-B0561S4

Spironolactone-d6-1

Spironolactone-d₆-1 is the deuterium labeled Spironolactone (HY-B0561). Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC₅₀=24 nM) and androgen receptor (IC₅₀=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca ²⁺ channels to exert antihypertensive effects .

HY-12542S

Dantrolene-13C3

Dantrolene- ¹³C₃ is the ¹³C₃ labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.

HY-B1193S

Terfenadine-d3

Terfenadine-d₃ ((±)-Terfenadine-d₃) is the deuterium labeled Terfenadine. Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC₅₀ of 204 nM . Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca2+ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9[2].

HY-14656S2

Diltiazem-d6 hydrochloride
Diltiazem-d₆ (hydrochloride) (CRD-401-d₆ (hydrochloride)) is deuterium labeled Diltiazem (hydrochloride). Diltiazem hydrochloride is a *Ca ²⁺* influx inhibitor (slow channel blocker or calcium antagonist).

HY-A0082S

Diphenidol-d10 hydrochloride

Diphenidol-d₁₀ (hydrochloride) (Difenidol hydrochloride-d₁₀) is deuterium labeled Diphenidol (hydrochloride). Diphenidol hydrochloride (Difenidol hydrochloride) is a non-selective muscarinic M₁-M₄ receptor antagonist, has anti-arrhythmic activity. Diphenidol hydrochloride is also a potent non-specific blocker of voltage-gated ion channels (Na ⁺, K ⁺, and Ca ²⁺) in neuronal cells. Diphenidol hydrochloride can be used in the study of antivertigo and antinausea .

HY-16935S

Mavatrep-d6
Mavatrep-d₆ (JNJ-39439335-d₆) is a deuterated labeled Mavatrep (HY-16935). Mavatrep (JNJ-39439335) is an orally active, selective and potent TRPV1 antagonist with high affinity for hTRPV1 channels (K_i=6.5 nM). Mavatrep antagonizes capsaicin-induced Ca ²⁺ influx with an IC₅₀ value of 4.6 nM. Mavatrep can be used in some studies of neuropathic pain .

HY-151547S

MRS4719-d3

MRS4719-d₃ is the deuterium labeled MRS4719 (HY-151547). MRS4719 is a potent P2X4 receptor antagonist with an IC₅₀ value of 0.503 μM for human P2X4 receptor. MRS4719 can reduce infarct volume and reduce brain atrophy, showing neuroprotective and neuro-rehabilitative activities in ischemic stroke model. MRS4719 also reduces ATP-induced [Ca ²⁺]_i influx in primary human monocyte-derived macrophages. MRS4719 can be used to research ischemic stroke .

HY-121186S

Bevantolol-d7 hydrochloride
Bevantolol-d₇ hydrochloride is the deuterium labeled Bevantolol hydrochloride (HY-121186). Bevantolol hydrochloride is a selective β1 and α1-adrenergic receptor antagonist with pK_i values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent Ca ²⁺ antagonist .

HY-166562S

Levomepromazine-d6 hydrochloride

Levomepromazine-d₆ hydrochloride (Methotrimeprazine-d₆ hydrochloride) is the deuterium labeled Levomepromazine hydrochloride. Levomepromazine (Methotrimeprazine) hydrochloride is an orally active antipsychotic compound and Ca ²⁺ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca ²⁺ levels. Levomepromazine hydrochloride has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine hydrochloride can induce adaptive ER stress and autophagy. In addition, Levomepromazine hydrochloride has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine hydrochloride can be used in the study psychiatric disorders and relieving nausea and vomiting .

HY-N2359S

Chelerythrine-d6 chloride

Chelerythrine-d₆ is the deuterium labeled Chelerythrine (HY-N2359). Chelerythrine is a natural alkaloid, acts as a potent and selective Ca ²⁺/phospholopid-dependent PKC antagonist, with an IC₅₀ of 0.7 μM . Chelerythrine has antitumor, antidiabetic and anti-inflammatory activity . Chelerythrine inhibits the BclXL-Bak BH3 peptide binding with an IC₅₀ of 1.5 μM and displaces Bax from Bcl-XL. Chelerythrine triggers apoptosis and autophagy .

Cat. No.	Product Name		Classification

HY-W250153

Adenosine 3'-phosphate 5'-phosphosulfate lithium		Nucleotide Analogs Adenine Nucleotide
Adenosine 3'-phosphate 5'-phosphosulfate lithium, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-164090

Adenosine 3'-phosphate 5'-phosphosulfate		Nucleotide Analogs Adenine Nucleotide
Adenosine 3'-phosphate 5'-phosphosulfate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

HY-W250153A

Adenosine 3'-phosphate 5'-phosphosulfate lithium, hydrate		Nucleotide Analogs Adenine Nucleotide
Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate, an adenine nucleotide derivative, is a selective P2Y1 antagonist with no effect on P2Y2, P2Y4, or P2Y6 receptors. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can competitive inhibit ADP-induced platelet aggregation, as well as the ability of ADP to cause shape change and increases in Ca ²⁺ in platelets, but had no effect on the inhibition of stimulated adenylate cyclase by ADP. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate is a co-substrate used for the sulfonation of glycans. Adenosine 3'-phosphate 5'-phosphosulfate lithium hydrate can be used for Golgi-resident PAP-specific 3'-phosphatase-coupled sulfotransferase assays, which as donor substrate to transfer a sulfonate group .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Ca2 antagonist

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products